Hydrograph aids LEAP lung cancer test with graphene

Executive Summary

• HydroGraph Inc. (a subsidiary of Hydrograph Clean Power Inc.) has entered into a commercialization agreement with Hawkeye Bio and Ease Healthcare to supply patented fractal graphene for the LEAP lung cancer screening test.
• The LEAP test is a non-invasive, radiation-free blood test designed to detect early-stage lung cancer with a 99.8% negative predictive value, targeting high-risk populations such as older smokers and first responders.
• HydroGraph’s explosion synthesis technology produces ultrapure graphene, which serves as the foundation for Hawkeye Bio’s patented nanoscale biosensors used in the LEAP diagnostic platform.

Key Details

• Parties Involved: HydroGraph Inc. (supplier), Hawkeye Bio (technology provider, Torrance, Calif.), and Ease Healthcare (marketing partner, Pasadena, Calif.).
• Product: LEAP (Lung Enzyme Activity Profile) early detection test.
• Technology: HydroGraph’s patented fractal graphene produced via explosion synthesis technology; Hawkeye Bio’s nanoscale graphene biosensors measuring enzymatic activity associated with inflammatory disease.
• Test Performance: 99.8% negative predictive value; non-invasive, radiation-free, highly sensitive.
• Target Demographics: Initially targeting high-risk populations including older smokers, military personnel, firefighters, and first responders.
• Market Context: Lung cancer is the leading cause of cancer deaths; estimated 125,000 deaths and 227,000 new cases in the U.S. in 2025. Screening compliance is currently low (2-6% of at-risk individuals).
• Future Plans: Future LEAP platforms plan to address 14 cancers, neurodegenerative diseases (Alzheimer's), and inflammatory conditions such as multiple sclerosis.
• Patent Portfolio: Hawkeye Bio holds global patents across the U.S., U.K., EU, Japan, Korea, Hong Kong, and Taiwan.

Notable Quotes

• "This partnership underscores the medical potential of high-purity graphene. Our ability to deliver graphene at scale supports groundbreaking diagnostics like Hawkeye's biosensors and Ease's LEAP test, ultimately saving lives through earlier detection and intervention." — Kjirstin Breure, President and CEO of HydroGraph.
• "Improved compliance with lung cancer screening guidelines may lead to earlier detection and improve radiotherapy and surgical outcomes. Our nano-scale graphene biosensors allow Ease Healthcare to bring LEAP testing to primary care physicians as a cost-effective diagnostic solution they can use in routine medical visits." — Andre de Fusco, CEO and Co-founder of Hawkeye Bio.